The use of Janus kinase inhibitors in the time of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

Peterson, Danielle; Damsky, William; King, Brett

Peterson, Danielle; Damsky, William; King, Brett.

Peterson D; Department of Dermatology, Yale School of Medicine, New Haven, Connecticut.
Damsky W; Department of Dermatology, Yale School of Medicine, New Haven, Connecticut.
King B; Department of Dermatology, Yale School of Medicine, New Haven, Connecticut. Electronic address: brett.king@yale.edu.

J Am Acad Dermatol ; 82(6): e223-e226, 2020 06.

Article in English | MEDLINE | ID: covidwho-276051

Subject(s)

Coronavirus Infections/complications; Immunomodulation; Janus Kinases/antagonists & inhibitors; Pneumonia, Viral/complications; Arthritis, Rheumatoid/drug therapy; Azetidines/adverse effects; Azetidines/therapeutic use; Betacoronavirus; COVID-19; Colitis, Ulcerative/drug therapy; Cytokines; Dermatitis, Atopic/drug therapy; Heterocyclic Compounds, 3-Ring/adverse effects; Heterocyclic Compounds, 3-Ring/therapeutic use; Humans; Nitriles; Pandemics; Piperidines/adverse effects; Piperidines/therapeutic use; Primary Myelofibrosis/drug therapy; Purines; Pyrazoles/adverse effects; Pyrazoles/therapeutic use; Pyrimidines/adverse effects; Pyrimidines/therapeutic use; Pyrroles/adverse effects; Pyrroles/therapeutic use; Randomized Controlled Trials as Topic; SARS-CoV-2; STAT Transcription Factors; Sulfonamides/adverse effects; Sulfonamides/therapeutic use

Fulltext

XML

PubMed Links

Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Pneumonia, Viral / Coronavirus Infections / Janus Kinases / Immunomodulation Type of study: Prognostic study / Randomized controlled trials Topics: Long Covid Limits: Humans Language: English Journal: J Am Acad Dermatol Year: 2020 Document Type: Article

Similar

MEDLINE

LILACS

LIS

Fulltext

XML

PubMed Links

Search on Google